Intermittent bisphosphonate therapy in postmenopausal osteoporosis: progress to date

Area of Science:

• Pharmacology
• Endocrinology
• Bone Metabolism

Background:

• Bisphosphonates are primary treatments for osteoporosis, demonstrating efficacy in reducing spinal and hip fractures.
• Oral bisphosphonates face challenges with adherence due to administration complexity and adverse effects.

Purpose of the Study:

• To evaluate the efficacy and adherence benefits of intermittent bisphosphonate dosing regimens.
• To explore newer administration intervals for bisphosphonates in managing postmenopausal osteoporosis.

Main Methods:

• Review of clinical studies on bisphosphonates, including daily, weekly, monthly, and infrequent intravenous (IV) administration.
• Analysis of bone mineral density (BMD) changes, fracture reduction rates, and biochemical markers.
• Assessment of patient adherence and adverse event profiles associated with different dosing frequencies.

Main Results:

• Weekly formulations of alendronic acid and risedronic acid offer comparable BMD and biochemical marker improvements to daily doses.
• Intermittent ibandronic acid (oral monthly, IV every 2-3 months) shows similar BMD increases to daily use and reduces vertebral fractures.
• Yearly zoledronic acid IV infusions are under investigation for fracture reduction efficacy.

Conclusions:

• Intermittent bisphosphonate regimens, particularly less frequent oral and IV options, may significantly enhance patient adherence.
• Confirmation of efficacy and safety for extended dosing intervals could improve long-term osteoporosis management and patient outcomes.